Schedule Issued for First Pradaxa Trial
Pradaxa lawsuits filed on behalf of patients who allegedly suffered internal bleeding due to the blood thinner continue to progress in U.S. District Court, Southern District of Illinois. An Order issued on April 9, 2014 established a pretrial schedule for the proceeding’s first bellwether Pradaxa trial. According to the Order, selection for the jury in the first Pradaxa trial is slated to begin on September 8, 2014. (In Re: Pradaxa Products Liability Litigation – MDL No. 2385)
Attorneys representing plaintiffs report that bellwether Pradaxa trials will likely provide valuable insight into how juries will rule in similar lawsuits. In some cases, if a jury rules in favor of either the plaintiff or the defendant in several lawsuits, the other party may wish to settle the rest of the claims outside of the court.
Pradaxa Trials Include Allegations of Bleeding
More than 2,500 Pradaxa lawsuits have been filed in the Southern District of Illinois, according to court documents. Plaintiffs allege that Pradaxa’s manufacturer, Boehringer Ingelheim Pharmaceuticals, neglected to provide warnings regarding the lack of an antidote for the internal bleeding that may sometimes occur with Pradaxa use. Additionally, plaintiffs claim that the manufacturer wrongly touted Pradaxa as an improvement to warfarin, a traditional and well-known blood thinner that has been used for several decades. Plaintiffs point out that while bleeding due to warfarin may be stopped with a vitamin K injection, there is no such reversal agent available for Pradaxa bleeding.
Pradaxa was introduced in the U.S. in October 2010, after the U.S. Food and Drug Administration approved it for use in patients with atrial fibrillation. According to the manufacturer, the blood thinner was intended to reduce the risk of stroke, heart attack and death as it would reduce the likelihood of the formation of clots. On April 7, 2014, Boehringer announced that the FDA had approved Pradaxa to include the pulmonary embolism and deep vein thrombosis treatments as well as to reduce the risk of recurrent deep vein thrombosis and pulmonary embolism in patients who have previously used the medication.
However, in February 2014, 7 Action News in Detroit aired a report in which the media station reported that Pradaxa may be the most complained about medication in the country. The FDA received 12,494 reports of injuries and 1,158 reports of deaths among Pradaxa users since the medication’s introduction, according to the broadcast. Many of these reports detailed episodes of uncontrollable internal bleeding.
Questions? Concerns? Contact Us Today
If you or someone you love has suffered from complications while taking Pradaxa or if you have questions about the first Pradaxa trial, contact the American Injury Attorney Group for more information. We can discuss legal options with patients who have been injured allegedly due to Pradaxa, and we can provide you with a free case evaluation to help you determine if you have a case. If we feel you are eligible to seek compensation for your injuries, we can connect you with an affiliated Pradaxa attorney who can assist you throughout the legal process.